L'Oreal stock: US unit settles first hair-relaxer cancer trial
Published on 11/17/2026 at 11:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSL'Oreal faces fresh legal exposure
- Four women reached a confidential settlement with L'Oreal's US subsidiary during a Chicago trial.
- More than 12,700 related claims are centralized in federal court, while L'Oreal maintains confidence in its product safety.
L'Oreal's US subsidiary reached a settlement with four women during the first trial over alleged cancer links to hair-relaxer products, Reuters reported on Monday, November 16, 2026. The agreement was reached in Chicago for a confidential amount, according to the plaintiffs' attorneys.
The women said chemical hair straightening products had contributed to gynecological cancers. They sued L'Oreal's US subsidiary and other manufacturers in Cook County, Illinois, in 2023 and 2024. The trial began on November 9 with jury selection.
Legal claims remain broader
The settlement covers the first cases to reach trial but leaves a much wider legal dispute in place. More than 12,700 related claims are centralized before a federal judge in Chicago, while additional cases have been filed in state courts. Arizona and Minnesota have also sued L'Oreal this year over allegations concerning product safety disclosures.
L'Oreal said its highest priority is consumer health and wellbeing and that it remains confident in the safety of its SoftSheen-Carson products, which include hair relaxers. The company told Reuters that L'Oreal USA follows regulations in every market and subjects its products to rigorous scientific safety evaluations. L'Oreal has also said an earlier National Institutes of Health study did not establish a causal link between the products and the conditions alleged by plaintiffs.
L'Oreal stock traded at 448.60 euros on Lang & Schwarz at 11:49 CET on Tuesday, November 17, 2026, 0.33 percent below the Xetra close of Monday, November 16. The Xetra closing price was 450.10 euros, according to De Belegger.
L'Oreal S.A. market facts
- Company: L'Oreal S.A.
- ISIN: FR0000120321
- Lang & Schwarz: 448.60 euros at 11:49 CET, November 17, 2026
- Xetra close: 450.10 euros, November 16, 2026
- Change: 0.33 percent below the Xetra close
The CAC 40 provides the relevant French-market backdrop for L'Oreal.
